COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,580 Articles (22,415 medRxiv, 8,165 bioRxiv)

Most recent first Previous |  Page 903: Articles 9021-9030  | Next

Germinal center-derived broadly neutralizing antibodies adapt to SARS-CoV-2 antigenic drift
Shitaoka, K., Kawano, Y., Higashiura, A., Mizoguchi, Y., Hashiguchi, T., Nishimichi, N., Huang, S., Ito, A., Yamamoto, A., Ohki, S., Kanda, M., Taniguchi, T., Yokosaki, Y., Okada, S., Sakaguchi, T., Yasuda, T.
10.1101/2022.01.26.477937 — Posted: 2022-01-27
Serum proteomics identifies immune pathways and candidate biomarkers of coronavirus infection in wild vampire bats
Becker, D., Lei, G.-S., Janech, M. G., Brand, A. M., Fenton, B., Simmons, N. B., Neely, B. A.
10.1101/2022.01.26.477790 — Posted: 2022-01-27
Ultraviolet Dosage and Decontamination Efficacy was Widely Variable Across 14 UV Devices after Testing a Dried Enveloped Ribonucleic Acid Virus Surrogate for SARS-CoV-2
Buhr, T. L., Borgers-Klonkowski, E., Gutting, B. W., Hammer, E. E., Hamilton, S. M., Huhman, B. M., Jackson, S. L., Kennihan, N. L., Lilly, S. D., Little, J. D., Luck, B. B., Matuczinski, E. A., Miller, C. T., Sides, R. E., Yates, V. L., Young, A. A.
10.1101/2022.01.27.478063 — Posted: 2022-01-27
The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition
Sacco, M. D., Hu, Y., Gongora, M. V., Meilleur, F., Kemp, M. T., Zhang, X., Wang, J., Chen, Y.
10.1101/2022.01.26.477774 — Posted: 2022-01-27
Effect of SARS-CoV-2 spike mutations on its activation by TMPRSS2 and TMPRSS13
Stevaert, A., Van Berwaer, R., Raeymaekers, V., Laporte, M., Naesens, L. M. J.
10.1101/2022.01.26.477969 — Posted: 2022-01-27
Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19
Peddireddy, S. P., Rahman, S. A., Cillo, A. R., Vijay, G. M., Somasundaram, A., Workman, C. J., Bain, W., McVerry, B. J., Methe, B., Lee, J. S., Ray, P., Ray, A., Bruno, T. C., Vignali, D. A., Kitsios, G. D., Morris, A., Singh, H., Sarkar, A., Das, J.
10.1101/2022.01.24.477545 — Posted: 2022-01-27
Defining the Substrate Envelope of SARS-CoV-2 Main Protease to Predict and Avoid Drug Resistance
Shaqra, A. M., Zvornicanin, S., Huang, Q. Y., Lockbaum, G. J., Knapp, M., Tandeske, L., Barkan, D. T., Flynn, J., Bolon, D. N., Moquin, S., Dovala, D., Kurt Yilmaz, N., Schiffer, C. A.
10.1101/2022.01.25.477757 — Posted: 2022-01-27
Impact of various vaccine boosters on neutralization against Omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine
Huang, Q., Zeng, J., Lang, Q., Gao, F., Liu, D., Tian, S., Shi, R., Luo, L., Wang, H., Hu, L., Jiang, L., Liu, Y., Li, K., Wu, Y., Xu, J., Jiang, W., Guo, N., Chen, Z., Hao, X., Jin, R., Yan, J., Sun, Y.
10.1101/2022.01.25.476850 — Posted: 2022-01-27
TNFα-producing CD4+ T cells dominate the SARS-CoV-2-specific T cell response in COVID-19 outpatients and are associated with durable antibodies
van der Ploeg, K., Kirosingh, A. S., Mori, D. A. M., Chakraborty, S., Hu, Z., Seivers, B. L., Jacobson, K. B., Bonilla, H., Parsonnet, J., Andrews, J. R., Press, K. D., Ty, M. C., Ruiz-Betancourt, D. R., de la Parte, L., Tan, G. S., Blish, C. A., Takahashi, S., Rodriguez-Barraquer, I., Greenhouse, B., Singh, U., Wang, T. T., Jagannathan, P.
10.1101/2022.01.25.22269670 — Posted: 2022-01-26
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
Hager, K. J., Marc, G. P., Gobeil, P., Diaz, R. S., Heizer, G., Llapur, C., Makarkov, A. I., Vasconcellos, E., Pillet, S., Riera, F., Bhutada, K., Wolff, P. G., Wallace, G., Aazami, H., Jones, C. E., Polack, F. P., Atkins, J., Boulay, I., Dhaliwall, J., Charland, N., Couture, M., Jiang-Wright, J., Landry, N., Lapointe, S., Lorin, A., Mahmood, A., Moulton, L. H., Pahmer, E., Parent, J., Saxena, P., Seguin, A., Tran, L., Breuer, T., Ceregido, M. A., Koutsoukos, M., Roman, F., Namba, J., D'Aoust, M.-A., Trepanier, S., Kimura, Y., The CoVLP Study Team, , Ward, B. J.
10.1101/2022.01.17.22269242 — Posted: 2022-01-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).